{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:11:48Z","timestamp":1792512708647,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtha.2025.11.017","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:15:34Z","timestamp":1765782934000},"page":"1130-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.11.017_bib1","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2025.11.017_bib3","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.11.017_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11239-013-0939-3","article-title":"Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group","volume":"37","author":"Sakamoto","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.11.017_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1076029618764843","article-title":"A randomized multicenter trial comparing low-dose prednisolone versus observation for prevention of recurrences in adult immune thrombocytopenia","volume":"24","author":"Pirunsarn","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.11.017_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000521912","article-title":"Splenectomy outcomes in relapsed or refractory immune thrombocytopenia according to first-line intravenous immunoglobulin response","volume":"145","author":"Kwag","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V77.1.31.31","article-title":"High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura","volume":"77","author":"Cortelazzo","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ejh.12146","article-title":"Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia","volume":"91","author":"Gonzalez-Porras","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000442703","article-title":"Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study","volume":"135","author":"Park","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.11.017_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12185-024-03847-4","article-title":"Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings","volume":"120","author":"Obara","year":"2024","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000510676","article-title":"Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi Panel","volume":"144","author":"Cooper","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12185-020-02893-y","article-title":"Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice","volume":"112","author":"Iino","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/bjh.19345","article-title":"Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study","volume":"204","author":"Cooper","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-015-1793-1","article-title":"Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults","volume":"102","author":"\u010cervinek","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib20","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib21","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5045\/br.2022.2022043","article-title":"Management of immune thrombocytopenia: 2022 update of Korean experts recommendations","volume":"57","author":"Park","year":"2022","journal-title":"Blood Res"},{"key":"10.1016\/j.jtha.2025.11.017_bib23","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.11.017_bib24","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2016-01-690727","article-title":"Thrombopoietin receptor agonists shift the balance of Fc\u03b3 receptors toward inhibitory receptor IIb on monocytes in ITP","volume":"128","author":"Liu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"Schifferli","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/voxs.12554","article-title":"Platelet immunology from the inside out","volume":"15","author":"Semple","year":"2020","journal-title":"VOXS"},{"key":"10.1016\/j.jtha.2025.11.017_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2016.161968","article-title":"Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia","volume":"102","author":"Cines","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.11.017_bib29","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib30","first-page":"756","article-title":"Clinical practice updates in the management of immune thrombocytopenia","volume":"42","author":"Khan","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.jtha.2025.11.017_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2025.11.017_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-142788","article-title":"Efficacy Analyses from the immune thrombocytopenia (ITP) clinical development program for avatrombopag: comparisons with placebo and eltrombopag","volume":"136","author":"Tarantino","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.11.017_bib34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"Kuwana","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.11.017_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5421632","article-title":"Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies","volume":"2020","author":"Poordad","year":"2020","journal-title":"Int J Hepatol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625008979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:01:45Z","timestamp":1781452905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625008979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538783625008979"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}